Searchable abstracts of presentations at key conferences on calcified tissues

ba0001pp100 | Calciotropic and phosphotropic hormones and mineral metabolism | ECTS2013

A mixture of GOS/FOS ® added to a low calcium (ca) diet improved ca, phosphorus (p) and magnesium (mg) absorption: experimental model in normal growing rats

Bryk Gabriel , Chaves Macarena Gonzales , Marotte Clarisa , Medina Daniela , Coronel Magali Zeni , de Portela Maria Luz , Zeni Susana Noemi

A mixture of Galacto-oligosaccharides (GOS) and Fructooligosaccharides (FOS) are added to commercial infant formula to promote an intestinal microbiota similar to that prevalent in breast-fed infants to improve Ca bioavailability and general health, but their mechanisms are under debate.Our objective was to evaluate the beneficial effects of the mixture of GOS/FOS added to infant formulae, on the absorption of Ca, Mg and P of a low Ca diet. Changes in in...

ba0001pp335 | Osteoporosis: evaluation and imaging | ECTS2013

Usefulness of bone turnover markers in the evaluation of fracture risk in type 2 diabetes

Rozas-Moreno Pedro , Reyes-Garcia Rebeca , Garcia-Martin Antonia , Lopez-Gallardo Gema , Garcia-Fontana Beatriz , Morales-Santana Sonia , Munoz-Torres Manuel

Introduction: The utility of the determination of bone turnover markers in the evaluation of fracture risk at the patient level is not well-established. In type 2 diabetes (T2DM) there is an increased risk of fractures despite of higher bone mineral density. A recent study shows that a femoral neck T-score of −2.1 in males and −1.9 in females with T2DM present the same fracture risk than subjects without diabetes with a T-score −2.5 (Schwart...

ba0001pp421 | Osteoporosis: treatment | ECTS2013

The efficiency of bisphosphonates (alendronate, risedronate, ibandronate) for postmenopausal osteoporosis after 1 year of therapy

Paun Diana , Totolici Nicoleta , Chirita Monica , Petris Rodica , Dumitrache Constantin

Introduction: Bisphosphonates are drugs of first choice in the treatment of postmenopausal osteoporosis; they inhibit bone resorbtion.Aim: This study evaluates the efficiency of bisphosphonates (alendronic acid+cholecalciferol 70 mg/5600 IU per weekly vs risedronic acid 35 mg/weekly vs ibandronic acid 150 mg/monthly) after 1 year of therapy.Methods: We present the results of a retrospective study which included 40 women with postme...

ba0001pp448 | Osteoporosis: treatment | ECTS2013

Resolution of effects on bone turnover markers and bone mineral density after discontinuation of long-term bisphosphonate use

Benhamou Claude , De Villiers Tobias , Johnston C Conrad , Langdahl Bente , Saag Kenneth , Denker Andrew , Pong Annpey , McGinnis John P , Rosenberg Elizabeth , Santora Arthur

Relatively little is known about immediate consequences of continuing vs interrupting long-term bisphosphonate treatment. This report describes changes in bone turnover and BMD in a 1-year, dose-finding trial of the calcium-sensing receptor antagonist MK-5442 in postmenopausal, BP-treated women, randomized to continued alendronate 70 mg weekly, switch to placebo, or switch to MK-5442. Recruited women (n=526) had taken alendronate for ≥12 months and an oral BP fo...

ba0002p44 | (1) | ICCBH2013

A homozygous mutation in the DNA binding domain of human vitamin D receptor causes vitamin D resistant rickets

van der Eerden Bram , van der Heyden Josine , Hamburger Jan Piet , Schreuders-Koedam Marijke , Asmawidjaja Patrick , de Muinck Keizer-Schrama Sabine , Lubberts Erik , van Leeuwen Johannes , Drop Stenvert

In this case report, we present a brother and sister with hereditary vitamin D resistant rickets (HVDRR). Both children presented at the age of 18 months with severe rickets and elevated serum levels of 1,25-(OH)2D3. They differ from each other in that the girl presented with hypophosphatemia instead of hypocalcemia. Besides, she developed alopecia earlier than the boy and needed more 1,25-(OH)2D3 supplementation. Interestingly, the ...

ba0002p159 | (1) | ICCBH2013

Novel SLC34A3 mutation causing mild hypophosphataemia, hypercalciuria and nephrolithiasis but no clinical or radiological evidence of rickets

Steele Caroline , Bradbury Mark , Mughal M Zulf

Background: Genetic disorders of mineral metabolism causing nephrolithiasis and bone abnormalities are uncommon and have a varied clinical spectrum. Hypophosphataemic rickets with hypercalciuria (HHRH) is a rare autosomal-recessive condition, typically presenting with severe rickets and hypophosphataemia. Milder forms can present with hypercalciuria and nephrolithiasis without bone disease. The underlying pathophysiology is due to mutations in the SLC34A3 gene, which encodes t...

ba0003pp73 | Bone development/growth and fracture repair | ECTS2014

S.C. injection of recombinant human parathyroid hormone rhPTH(1--84) in thigh provides a more prolonged pharmacokinetic profile and a greater calcemic response when compared with injection in abdomen

Fox John , Garceau Roger , Lagast Hjalmar

Recombinant human parathyroid hormone (rhPTH) (1–84) is currently being developed as PTH replacement therapy for patients with hypoparathyroidism. Because rhPTH(1–84) is administered subcutaneously, we compared the pharmacokinetic profile of PTH(1–84) and the calcemic response following S.C. rhPTH(1–84) injection in thigh and abdomen.In this phase 1, open-label, three-way crossover study, healthy postmenopausal women received three ra...

ba0003pp220 | Osteoporosis: evaluation and imaging | ECTS2014

The fracture outpatient clinic: what is the additional value of vertebral assessments and which individuals should be more actively recruited?

Muilwijk Carolien , Lips Paul , Lems Willem , Bultink Irene , den Heijer Martin , de Jongh Renate

Fracture outpatient (FO) clinics aim to identify individuals at high fracture risk. Identification of individuals at high fracture risk has been improved since the introduction of vertebral fracture assessment (VFA). Unfortunately, participation rates in FO clinics are often low.The aim of this study is to i) assess the contributory value of VFA in addition to BMD measurements in identifying individuals with high fracture risk; ii) assess characteristics...

ba0004p129 | (1) | ICCBH2015

Cortical area and volumetric density during pubertal growth: longitudinal analysis in black and white South African adolescent males

Schoenbuchner Simon , Ward Kate , Norris Shane , Prentice Ann , Pettifor John

Skeletal development during childhood and adolescence is an important determinant of adult bone health. Patterns of growth differ between populations, but it is unclear how these differences relate to changes in bone size and volumetric density. We aimed to examine ethnic differences in skeletal phenotype in the context of pubertal growth and development in 279 adolescent males from Johannesburg, South Africa.We performed annual peripheral quantitative c...

ba0005p10 | Arthritis and other joint diseases: translational and clinical | ECTS2016

Identifying cell populations coupling inflammation to osteoresorption in arthritis

Mosler Elvira Lazic , Flegar Darja , Sucur Alan , Fadljevic Martina , Kelava Tomislav , Markotic Antonio , Ivcevic Sanja , Zrinski-Petrovic Katerina , Katavic Vedran , Grcevic Danka , Kovacic Natasa

Rheumatoid arthritis (RA) is characterised by periarticular bone destruction leading to permanent disability. Some other forms of arthritis, such as arthritis in systemic lupus erythematosus (SLE), rarely produce bone lesions. Corresponding to that, inactivation of Fas produces a murine SLE-like phenotype, but alleviates bone loss during antigen-induced arthritis (AIA). Aim of this study was to identify cell populations differentially regulated in non-resorptive vs. resorptive...